Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer

Journal of Surgical Oncology

Volumn 106, Issue 1, 2012, Pages 57-61

  Yang, Guo Liang ^a   Zhang, Lian Hua ^a   Bo, Juan Jie ^a   Hou, Xiao Jiao ^b   Chen, Hai Ge ^a   Cao, Ming ^a   Liu, Dong Ming ^a   Huang, Yi Ran ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Bladder cancer; HMGB1; Immunohistochemistry; Prognosis

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER PROGNOSIS; CANCER STAGING; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TISSUE SECTION;

ADULT; AGED; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGB1 PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; URINARY BLADDER NEOPLASMS;

EID: 84862797755     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23040     Document Type: Article

References (31)

1. Jemal A, Siegel R, Xu J, et al.: Cancer statistics, 2010. CA Cancer J Clin 60:277-300.
2. Zhang W, Xiang YB, Liu ZW, et al.: Trends analysis of common urologic neoplasm incidence of elderly people in Shanghai, 1973-1999. Ai Zheng 2004;23:555-558.
3. Ghoneim MA, Abdel-Latif M, el-Mekresh M, et al.: Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol 2008;180:121-127.
4. Shariat SF, Karakiewicz PI, Palapattu GS, et al.: Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: A contemporary series from the Bladder Cancer Research Consortium. J Urol 2006;176:2414-2422. (Pubitemid 44755069)
5. Bianchi ME, Beltrame M: Upwardly mobile proteins. Workshop: The role of HMG proteins in chromatin structure, gene expression and neoplasia. EMBO Rep 2000;1:109-114.
6. Czura CJ, Wang H, Tracey KJ: Dual roles for HMGB1: DNA binding and cytokine. J Endotoxin Res 2001;7:315-321. (Pubitemid 33041072)
7. Muller S, Scaffidi P, Degryse B, et al.: New EMBO members' review: The double life of HMGB1 chromatin protein: Architectural factor and extracellular signal. EMBO J 2001;20:4337-4340. (Pubitemid 32772027)
8. Lotze MT, Tracey KJ: High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 2005;5:331-342. (Pubitemid 40516158)
9. Kostova N, Zlateva S, Ugrinova I, et al.: The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem 2010;337:251-258.
10. Poser I, Golob M, Buettner R, et al.: Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol 2003;23:2991-2998. (Pubitemid 36403094)
11. Akaike H, Kono K, Sugai H, et al.: Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer. Anticancer Res 2007;27:449-457.
12. Volp K, Brezniceanu ML, Bosser S, et al.: Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut 2006;55:234-242. (Pubitemid 43117284)
13. Ishiguro H, Nakaigawa N, Miyoshi Y, et al.: Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 2005;64:92-100. (Pubitemid 40734743)
14. Wu D, Ding Y, Wang S, et al.: Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol 2008;216:167-175.
15. Liu Y, Xie C, Zhang X, et al.: Elevated expression of HMGB1 in squamous-cell carcinoma of the head and neck and its clinical significance. Eur J Cancer 46:3007-3015.
16. Schlueter C, Weber H, Meyer B, et al.: Angiogenetic signaling through hypoxia: HMGB1: An angiogenetic switch molecule. Am J Pathol 2005;166:1259-1263. (Pubitemid 40524448)
17. Dong Xda E, Ito N, Lotze MT, et al.: High mobility group box I (HMGB1) release from tumor cells after treatment: Implications for development of targeted chemoimmunotherapy. J Immunother 2007;30:596-606. (Pubitemid 47229694)
18. Kuniyasu H, Oue N, Wakikawa A, et al.: Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 2002;196:163-170. (Pubitemid 34110897)
19. Kepp O, Tesniere A, Schlemmer F, et al.: Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 2009;14:364-375.
20. McKinney K, Prives C: Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Mol Cell Biol 2002;22:6797-6808.
21. Stros M, Muselikova-Polanska E, Pospisilova S, et al.: High-affinity binding of tumor-suppressor protein p53 and HMGB1 to hemicatenated DNA loops. Biochemistry 2004;43:7215-7225. (Pubitemid 38720539)
22. Livesey KM, Tang D, Zeh HJ, et al.: Not just nuclear proteins: 'Novel' autophagy cancer treatment targets-p53 and HMGB1. Curr Opin Investig Drugs 2008;9:1259-1263.
23. Stros M, Ozaki T, Bacikova A, et al.: HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter. J Biol Chem 2002;277:7157-7164. (Pubitemid 34953105)
24. Uramoto H, Izumi H, Nagatani G, et al.: Physical interaction of tumour suppressor p53/p73 with CCAAT-binding transcription factor 2 (CTF2) and differential regulation of human high-mobility group 1 (HMG1) gene expression. Biochem J 2003;371:301-310. (Pubitemid 36547612)
25. Jiao Y, Wang HC, Fan SJ: Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin 2007;28:1957-1967. (Pubitemid 350198338)
26. Agresti A, Lupo R, Bianchi ME, et al.: HMGB1 interacts differentially with members of the Rel family of transcription factors. Biochem Biophys Res Commun 2003;302:421-426. (Pubitemid 36397940)
27. Das D, Peterson RC, Scovell WM: High mobility group B proteins facilitate strong estrogen receptor binding to classical and half-site estrogen response elements and relax binding selectivity. Mol Endocrinol 2004;18:2616-2632. (Pubitemid 39482053)
28. El Marzouk S, Gahattamaneni R, Joshi SR, et al.: The plasticity of estrogen receptor-DNA complexes: Binding affinity and specificity of estrogen receptors to estrogen response element half-sites separated by variant spacers. J Steroid Biochem Mol Biol 2008;110:186-195.
29. Ghavami S, Rashedi I, Dattilo BM, et al.: S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol 2008;83:1484-1492. (Pubitemid 351960330)
30. Palumbo R, Galvez BG, Pusterla T, et al.: Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation. J Cell Biol 2007;179:33-40. (Pubitemid 47606681)
31. Taguchi A, Blood DC, del Toro G, et al.: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000;405:354-360. (Pubitemid 30337069)